NasdaqGM:NAMSBiotechs
Why NewAmsterdam Pharma (NAMS) Is Down 6.2% After EMA Backs Ubeslo And Evlarco Approval
NewAmsterdam Pharma and Menarini Group previously announced that the EMA’s CHMP issued a positive opinion recommending marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) in European patients with primary hypercholesterolemia and mixed dyslipidemia.
This opinion, backed by extensive Phase 2 and Phase 3 data showing meaningful LDL-C reductions with placebo-like tolerability, could reshape NewAmsterdam’s commercial outlook through...